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Infections are responsible for over half a million neonatal deaths every year 
(Lawn et al., 2014). Thus, there is huge interest in leveraging maternal immunization 
against infectious diseases to grant fetal protection during its development through the 
vertical transferring of IgG antibodies, the only Ig subclass that can significantly cross 
the placental barrier. 
Studies about vertical immunization rely on in-vitro models to extrapolate 
physiological conditions of the human placenta. The BeWo Transwell model (Bode et 
al., 2006) presents itself as a reliable model to mimic the transplacental transport 
mechanism of antibodies (Ellinger et al., 1999; Poulsen et al., 2009). However, despite 
being a consolidated method, the BeWo Transwell preparation has a wide variation of 
parameters. Additionally, up to this date, evaluation of preferential transfer of IgG 
considering its subclasses and specificities have not been reported in the BeWo 
Transwell, limiting the ability to assess the reliability of this model for antibody 
translocation studies. 
Therefore, the focus of this project is to investigate the effect of IgG subclasses 
and specificity in the placental transferring of 16 CMV antibodies designed in-house 
by using the BeWo Transwell model in order to contribute to in-vitro studies about 
maternal immunization. However, the success of this study relies on first optimizing 
the Transwell model towards a more time-efficient preparation to reach monolayer 
confluency by investigating three variables: membrane coating, cell seeding density, 
and incubation time.  
Results indicate that the final ideal parameters for the Transwell setup are 
collagen-coat over the microporous membrane, seeding cell density of 6 × 10! 
cells/#$" (200,000 cells/well for the 24-well plate), and incubation time of 72 hrs (3 
i
ii 
days). Comparison of the preferential transfer of IgG across this BeWo Transwell 
model revealed that IgG4 1G2 has the best transferring performance. In the context of 
IgG subclasses, IgG3 has the worst relative transferring, regardless of its specificity. 
On the other hand, IgG4 and IgG2 show the best relative transferring performance 
overall. Analysis of the data by mAb specificities reveals that IgG 1G2 has the best 
transferring performance across the cell layer, regardless of its subclass. 
Future directions include quantifying the IgG transferring across the cell layer 
for a statistical analysis, and investigations about how mAb specificity influences IgG 
subclass transport across the BeWo cell layer, and how the transferring is compared to 
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Introduction 
Monoclonal antibodies in immunotherapy 
Antibodies, also called immunoglobulins (Ig), are glycoprotein molecules 
produced by plasma cells that play a critical role in identifying and binding to foreign 
objects such as bacteria and viruses, assisting the immune system in fighting against 
diseases (Branden & Tooze, 1999). Monoclonal antibodies (mAbs) work in a similar 
fashion but are engineered in the laboratory and intentionally tailored to target an 
antigen. The ability to design specific modifications in mAbs, make them a powerful 
tool to effectively and safely target diseases that, up to recent years, did not have a cure, 
and to leverage immunotherapy in several contexts, from cancer therapy to vaccine 
development (Brekke & Sandlie, 2003). Currently, monoclonal antibody research is 
one of the fastest-growing fields in biotechnology due to its pharmaceutical 
applications. For instance, the top selling drug globally in 2019 was a mAb (Urquhart, 
2020). 
 
Immune system and the role of antibodies 
Our immune system can be segmented into innate and adaptive. The first line 
of defense against general pathogens, the innate immune system does not change based 
on its exposure to diseases. The adaptive immune system, on the other hand, is activated 
by signals delivered from the innate system and uses an immunological memory to store 
information about previous threats. By making use of lymphocytes and antibodies, the 
adaptive immune system uses antigens to trigger an immune response against specific 
diseases. In antibody responses, antibodies circulate in the bloodstream and bind to 
foreign substances, blocking the pathogen from binding to receptors on host cells and 
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marking them for destruction. Given their specificity and efficacy, antibodies are key 
components of our immune defense (Hoebe et al., 2004). 
There are five antibody types circulating in the human body: IgA, IgD, IgE, 
IgG, and IgM. Out of these antibody isotopes, the IgG is the most common antibody in 
the plasma, accounting for 70% of immunoglobulins in the human body (Llewelyn et 
al., 1992). IgG is also the only antibody isotope transferred in significant quantities 
from the mom to the fetus through the placental tissue during pregnancy, making it 
particularly important for studies on maternal vaccination, passive immunization, and 
neonatal infection (Malek et al., 1996). 
 
Structure and characterization of IgG 
IgG antibodies have a Y-shape, where the stem of the Y characterizes the Fc 
fragment – part that interacts with receptors of the immune response. The two arms on 
the Y-shape are called Fab fragments, where two antigen-binding sites allow the 
recognition of target sequences and formation of immune complexes. IgG antibodies 
have a molecular weight of approximately 150 kDa and are composed of two different 
peptide chains: the light chain and the heavy chain. The light chain is approximately 25 
kDa and is only present on the 
Fab fragments. The heavy chain 
is approximately 50 kDa and is 
present both in the Fc and Fab 
regions. Each IgG molecule is 
composed of two heavy chains, 
linked with each other by 
disulfide bonds, and two light 
Figure 1: Stuctural schematic of IgG 
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chains, linked with one heavy chain each through a disulfide bond as well. In all IgG, 
the two heavy chains and the two light chains are equivalent, giving the antibody two 
identical antigen-binding sites (Branden & Tooze, 1999). IgG monoclonal antibodies 
conserve this same general structure, which is represented in Figure 1. 
There are four subclasses of IgG, named in the order of decreasing abundance 
in the blood: IgG1, IgG2, IgG3, and IgG4 (Schur, 1988). Although the tertiary structure 
of IgGs is relatively similar, the location and number of interchain-disulfide bonds 
differs for each subclass. The aminoacid sequence of IgG subtypes are approximately 
90% homologous in the heavy chain, with differences found in the CH domains 
(Jefferis et al., 1985; Vidarsson et al., 2014). These modifications give each subclass 
different characteristics in immune complex formation, half-life, and placental 
transport, for example (Vidarsson et al., 2014). 
 
 
Figure 2: Structure of IgG subclasses. IgG: immunoglobulin G; FR: framework region; VL: variable 
region of light chain; VH: variable region of heavy chain; CL constant region of light chain; CH1: 
constant region of heavy chain 1; S-S: disulfide bond; H: hinge region; CH2: constant region of heavy 
chain 2; CH3: constant region of heavy chain 3; CDR: complementarity-determining region; V: variable 
region; D: diversity segment; J: joining segment; CHS: coding region at the C-terminal end of a secreted 
immunoglobulin heavy chain; H1: hinge region 1; H2: hinge region 2; H3: hinge region 3; H4: hinge 
region 4. (Structure of the IgG Subclasses - UpToDate, n.d.) 
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FcRn receptor as a mediator for neonatal immunization through vertical IgG transferring 
Newborn infants present an immature immune system and are particularly 
susceptible to vaccine-preventable diseases. However, natural neonatal immunity can 
be enhanced still at a gestational stage through maternal immunization and the resulting 
vertical (mother-to-child) transfer of pathogen-specific antibodies across the placenta 
(Healy, 2012; Kristoffersen, 2000; Marchant et al., 2017; Meng et al., 2018; Patel et al., 
2019). In humans, the placenta acts as a cellular barrier separating the maternal and 
fetal blood. Several molecular substances are actively and passively transferred through 
the placenta to the fetus, from small molecular weight substances such as ions and 
aminoacids to high molecular weight proteins such as IgG antibodies (Knipp et al., 
1999; Little & VanBeveren, 1996; Malek et al., 1998; Pitcher-Wilmott et al., 1980). 
In humans, the mother-to-child IgG transfer occurs across the 
syncytiotrophoblast of the placenta (N. E. Simister et al., 1996; Neil E. Simister, 1998). 
Syncytiotrophoblasts are in the maternal blood and involve the fetal blood, serving as 
a histological barrier. The Fc neonatal receptor (FcRn) is expressed in the internal 
vesicles of the syncytiotrophoblast and is responsible for mediating the transplacental 
translocation of maternal IgG (F. W. R. Brambell et al., 1964; F. W. Rogers Brambell, 
1966; Israel et al., 1996; Roopenian et al., 2003). The human FcRn has only one 
potential glycosylation site (N102) and does not bind its IgG ligands at physiological 
pH (7.4). However, when the endosome is acidified (pH ≤ 6.5), the histidine residues in 
IgG are protonated and the FcRn binds to the maternal IgG, facilitating its transport into 
the fetal circulation (Chaudhury et al., 2003; Gastinel et al., 1992; Roopenian et al., 
2003). Once in the baby’s bloodstream, these IgGs can protect the fetus from infections 
in the developmental stage and the child during early life, since the antibodies stay in 
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circulation for 6-12 months after birth (Kılıç et al., 2003; Leuridan et al., 2011; Leuridan 
& Van Damme, 2007). 
 
 
Figure 3: Human placenta and IgG transport mediated by the FcRn receptor. (a) Fetus in developing 
stages attached to an umbilical cord and uterine wall. (b) Cross-sectional view of the placenta. (c) 
Detailed diagram of the materno-fetal IgG transfer in humans across the syncytiotrophoblast of the 
placenta, mediated by the FcRn receptor. Image adapted from (Pemathilaka et al., 2019).  
 
Infections are responsible for over half a million neonatal deaths every year 
(Lawn et al., 2014). Thus, there is huge interest in leveraging maternal immunization 
against infectious diseases to grant fetal protection during its development and boost 
the inexperienced immune system of neonates through the vertical transferring of IgG. 
Previous studies have demonstrated that each IgG subclass presents a different 
transport capacity across the placental tissue, with preferential transfer following the 
sequence: IgG1 > IgG4 > IgG3 > IgG2 (Bt et al., 1996; Malek et al., 1994, 1996). 
However, antibody specificities might influence the placental transport of different IgG 
subclasses since there is variation in the subclass response to different antigens and each 
subclass has a different affinity to the IgG-transporting FcRn receptors (Ferrante et al., 
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1990; Wesumperuma et al., 1999). Therefore, it is crucial for studies in maternal 
immunotherapy to characterize IgG transfering in the context of IgG subclasses and 
specificities.  
 
BeWo Transwell assay as a model for placental translocation studies 
Due to ethical reasons, in-vivo IgG transferring studies from mother-to-child 
during fetal development remain extremely limited (Constantinos et al., 2011). Some 
animals, like rodents, can assist with information on placental transfer of substances 
and their potential effects to the fetus. However, the placenta is a species-specific organ 
and any extrapolation from animal models to humans could lead to inaccuracies 
(Schmidt et al., 2015). In order to avoid ethical issues and overcome species-specific 
differences, several ex-vivo and in-vitro models using human cells or tissue have been 
recently proposed (Aengenheister et al., 2018; Ellinger et al., 1999; Levkovitz et al., 
2013; Mathiesen et al., 2014).  
The ex-vivo placental perfusion model uses a human term placenta obtained 
directly after birth to establish a dynamic circulation mimicking the in-vivo system 
(Grafmüller et al., 2013; Mathiesen et al., 2014). Despite bypassing the extrapolation 
from animal data, this model has a perfusion duration of only 6 hours, has a low 
throughput, is hard to reproduce due to interindividual differences, and has a success 
rate dependent on the availability of fresh placentas, informed consent, and time-
consuming procedures affected by a high leakage or failure rate (Hutson et al., 2011; 
Poulsen et al., 2009).  
On the other hand, in-vitro translocation models are more widely used due to 
their easier set-up and convenience for lab personnel. Such models use a confluent 
monolayer of cells cultivated over a porous membrane to study the transport of 
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substances. Despite not fully simulating the physiological structure and factors 
influencing the placental barrier, this model is able to accurately represent perfusion 
preferences of substances that agree with ex-vivo results and mimic transplacental 
transport mechanisms (Ellinger et al., 1999; Poulsen et al., 2009).  
The setup of in-vitro translocation models is depicted in Figure 4. It consists of 
an upper chamber delimited by a Transwell insert, embedded into a lower chamber. The 
Transwell insert has a “cup-like” shape 
and its bottom is composed of a 
microporous membrane to allow 
perfusion of the studied substance. To 
model histological transfer barriers, a 
cell layer is cultivated on top of a matrix 
layered on the microporous membrane.  
While much of the research 
community has focused on utilizing the BeWo Transwell model to study the transport 
of small substances and nano-particples, this experimental setup can have profound 
implications in transport studies of IgG (Aengenheister et al., 2018; Huang et al., 2016). 
In the past, there have been successful studies on the reduced transcytosis of IgG2 and 
the half-life of IgG3, for example, which were conducted using the BeWo Transwell 
model (Stapleton et al., 2011, 2019). However, up to this date, no study has attempted 
to characterize the preferential IgG transferring in the BeWo Transwell model in the 
context of subclasses and specificities. Without knowing how the IgG transfer in this 
model compares to those in-vivo, extrapolation to human physiology of maternal 
immunization studies using the BeWo Transwell remains limited. 
Figure 4: Schematic of the Transwell in-vitro 
translocation model 
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The reliability of placental transport studies using this setup rely on the 
confluency of the cell monolayer and its resemblance to human physiology. In the past, 
several studies attempted to optimize this model (Aengenheister et al., 2018; Bode et 
al., 2006; Huang et al., 2016). 
In order to simulate the in-vivo placental translocation of IgG, researchers 
attempted to culture isolated syncytiotrophoblasts, but reported that such cell culture is 
hard to obtain (Bode et al., 2006; Ellinger et al., 1999). Fortunately, BeWo cells derived 
from human choriocarcinoma retain several characteristics of trophoblasts, the 
undifferentiated cell layer of syncytiotrophoblasts, such as placental hormone secretion 
and permeability. More importantly, BeWo cells express an IgG receptor structurally 
and functionally homologous to the human FcRn, making them a good cell line to 
extrapolate the physiology of syncytiotrophoblasts (Ellinger et al., 1999). Thus, BeWo 
cells have been used as the “gold standard” in in-vitro models to investigate the 
placental transport of several nutrients, proteins, and compounds, such as IgG (Ellinger 
et al., 1999; Huang et al., 2016; Moe et al., 1994; Schmid et al., 2003). 
However, there is still doubt about the need of the matrix layer between the 
microporous membrane and the cell layer. Some research groups and unpublished 
studies conducted in the Ackerman Lab indicate that coating the Transwells with 
placental collagen is essential for the monolayer formation (Bode et al., 2006; Huang 
et al., 2016). Contrastingly, others reported achieving monolayer integrity without a 
matrix layer and observed no transport difference between collagen-coated and 
uncoated membranes (Aengenheister et al., 2018; Stapleton et al., 2011, 2019). 
Questions also remain about the number of seeded cells and their incubation 
time to reach a confluent cell monolayer. While previous studies reported achieving 
monolayer integrity with overnight cell incubation (Stapleton et al., 2011, 2019), other 
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authors and unpublished studies conducted in the Ackerman Lab indicate the need of a 
3-7 days incubation period for such results (Aengenheister et al., 2018; Bode et al., 
2006; Cartwright et al., 2012; Huang et al., 2016; Rytting et al., 2012). Additionally, 
there is a wide variation in the seeding density of cells. In previous studies, monolayer 
confluency was achieved with cell seeding density ranging from 1.0 × 10! 
cells/#$"(Aengenheister et al., 2018; Cartwright et al., 2012; Liu et al., 1997) to 1×10# 
cells/#$"(Huang et al., 2016).  
Therefore, much remains in terms of optimizing the BeWo Transwell model for 
translocation studies as well as exploring IgG transferring in this model as a means to 
characterize the effect of IgG subclasses and specificity in antibody transferring across 
the placental tissue in-vitro. 
 
Antibody Selection & Justification 
Cytomegalovirus (CMV) is a herpes virus that causes infection with serious 
developmental impacts for newborns, who are particularly susceptible to developing 
hearing loss, blindness, and cognitive delay in cases of congenital infection (Dollard et 
al., 2007; Pass et al., 2006). In the United States, CMV is estimated to be the leading 
cause of hearing loss in newborns, accounting for 15-21% of cases of hearing loss at 
birth (Morton & Nance, 2006). 
Studies about herpes simplex virus infections have shown that behavioral 
sequelae in the fetus can be prevented by maternal immunization (Patel et al., 2019). 
Such findings lay the groundwork for investigations on maternal vaccination as a 
preventive method against neurotropic neonatal infections caused by other herpes 
viruses, such as CMV. 
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Previous research conducted at the Ackerman Laboratory reported the CMV-
specificity of 16 different anti-CMV antibodies, which were genetically designed and 
engineered in the lab by modifying IgG1, IgG2, IgG3, and IgG4 mAbs with four DNA 
fragments: 1G2, 8I21, 9I6, and ITC33. As the unpublished data on Figure 5 shows, 
inserting these DNA sequences into the backbone of IgG equipped the antibodies with 
the feature of recognizing glycoprotein B and the glycoprotein pentamer. Such antigens 
are found on the surface of the CMV virus (Chandramouli et al., 2015, 2017; Silvestri 
et al., 1993), and antibodies that are able to recognize these DNA fragments are strong 




Figure 5: CMV-specificity of antibodies designed in-house. IgG2 data is not depicted as the mAbs were 
produced and analyzed in a subsequent study conducted by Andrew Hederman. (a) and (b) 1G2 and 
ITC33 mAbs bind CMV gB. (c) and (d) 8I21 and 9I6 mAbs bind CMV pentamer. Figure from unpublished 
data, Ackerman Lab. Data was collected by Sayuri Magnabosco and Jennifer Lai, and graphics were 
made by Andrew Hederman.  
 
Given the nature of the mother-to-child transmission of the congenital CMV 
infection, viability of a CMV vaccine using such antibodies rely primarily on the 
effectiveness of antibody transferring across the placental tissue between the fetus and 
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expecting mother. However, without understanding how the IgG transport is affected 
by subclasses and specificities in a reliable in-vitro model, attempts to move to in-vivo 
testing and create a vaccine for CMV are limited.  
Considering the need in modeling IgG transferring across the placenta in-vitro, 
the vertical transmission of congenital CMV, and research efforts in our group around 
a CMV vaccine, we propose this study using the 16 CMV-specific IgG mAbs 
previously designed in the Ackerman Lab (Table 1).  
 
Table 1: Antibodies selected for this study 


































The FcRn-mediated transport of antibodies relies on the binding of IgG to FcRn 
through the Fc region of antibodies, a structural part that is generally conserved within 
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each IgG subclass, regardless of their specificities (Burmeister et al., 1994). Therefore, 
despite the CMV-specificity of the selected mAbs, results from this study will be able 
to contribute to discussions about general IgG preferential transfer across the placental 
tissue in in-vitro models. 
 
Objectives and Hypotheses 
The focus of this study is to investigate the effect of IgG subclasses and 
specificity in the placental transferring of antibodies by using the BeWo Transwell 
model in order to contribute to in-vitro studies about maternal immunization. However, 
the success of this project relies on first optimizing the Transwell model to study the 
transferring of IgG antibodies. Currently, the experimental preparation to achieve a 
confluent cell monolayer presents wide variation in the number of seeded cells and their 
incubation time, and divergent results on whether the collagen-coating of the 
microporous membrane is necessary to achieve monolayer confluency. Therefore, this 
research project aims to achieve the following goals: 
1. Optimize the BeWo Transwell assay via investigation of seeding cell density, 
incubation time, and presence/absence of a collagen matrix layer in order to 
obtain a confluent cell monolayer to be used in transport studies in-vitro.  
a. Hypothesis I: Transwells seeded with higher cell densities will require 
less incubation time to reach monolayer confluency. Fluorescence 
measurements in the lower chamber will correlate negatively with 
monolayer confluency, and there will be a point where no fluorescence 
in the lower chamber will be detected due to full retention of FITC-
dextran in the upper chamber of confluent monolayers.   
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2. Compare the preferential transfer of IgG across the placental tissue in-vitro 
using the BeWo Transwell model by analysis of 16 anti-CMV mAbs with 
different specificities and subclasses. 
a. Hypothesis II: All the samples will be able to cross the monolayer tissue, 
but at different amounts. Luminex analysis will indicate higher IgG 
concentrations in the lower chamber for antibody species that have the 
most efficient transferring across the cell layer. Extrapolation from 
human physiology indicates preferential transferring following the 
sequence: IgG1 > IgG4 > IgG3 > IgG2 (Bt et al., 1996; Malek et al., 
1994, 1996). Antibodies that present the same antigen specificity should 
demonstrate comparable IgG transferring capabilities. 
   
Materials and Methods 
General Experimental Design 
The experiments were designed in two phases. The first part involved testing 
the monolayer confluency on the Transwell inserts according to three variables: number 
of seeded cells, presence/absence of collagen as a matrix between the microporous 
membrane and the cell layer, and incubation time. Cell permeability based on 
fluorescence reading of FITC-dextran (40kDa) was then compared to determine 
optimized parameters for reaching monolayer confluency on the Transwell insert in the 
most time-efficient manner. In the BeWo monolayer, only IgG antibodies should be 
able to significantly cross the membrane once it has reached confluency. Thus, FITC-
dextran transport across the cell layer was used as an indicative of monolayer 
confluency. Experiments were performed in an iterative fashion, where the fluorescent 
14 
readouts guided further investigations on incubation time and/or cell seeding density. 
Detailed experimental conditions and protocols are explained in the sections below. 
The second part of the experiment involved using the optimized Transwell 
model to evaluate the transferring of 16 CMV-specific mAbs (IgG1, IgG2, IgG3, and 
IgG4 with 1G2, 8I21, 9I6, and ITC33 specificities). Samples were collected over time 
in order to characterize the preferential transferring of antibodies based on their 
subclasses and specificities. The overview of the experimental design is presented on 
Figure 6.  
 
 
Figure 6: Depiction of experimental design overview 
 
Throughout this project, we used 24-well Transwell plates with polyester inserts 
of pore size 0.4 μm, and 0.33 #$" growth area (Corning Costar), depicted in Figure 7. 
Despite having 24 inserts, this plate is designed by the manufacturer to accommodate 







Figure 7: Schematics of a 24-well Transwell plate.  (a) Picture of the Transells purchased for this project 
(Corning e-catalog). (b) Top view of the plate indicates the location of the 12 Transwell inserts, on rows 
B and C, highlighted in pink. Amplification of a well with the Transwell insert indicates the well setup 
and specifications provided by the manufacturer. 
 
Production of Antibodies 
Plasmids of the 16 CMV antibodies of interest in this study (Table 1) were 
generated in a previous project in our lab by Jennifer Lai, Sayuri Magnabosco, and 
Andrew Hederman. First, pMAZ vectors went under vector restriction. Enzymes NheI-
HF and BSSHII (NEB) were used for the pMAZ IgG1, IgG2, IgG3, and IgG4 and 
enzymes BSiWI-HF and BSSII (NEB) were used for pMAZ IgL. Next, the restricted 
products went under Gibson assembly reaction in VH/VL blocks to receive the DNA 
fragments encoding 1G2, 8I21, 9I6, and ITC33 specificities. The product was then 
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transformed into 5-alpha competent E.Coli (NEB). Colonies were picked and 
inoculated for a miniprep. To verify correct gene insertion, the miniprepped DNA was 
sent to Genewiz for sequencing and analyzed in Benchling. Plasmids with the correct 
insert were re-transformed, grown into LB cultures with Ampicillin, and their DNA 
was harvested using NucleoSpin Plasmid (no lid) purification kit (Machery-Nagel) and 
following the NucleoSpin Plasmid QuickPure protocol - isolation of high-copy plasmid 
DNA from E.coli (Machery-Nagel).  
To produce the antibodies used in this study, the DNA products previously 
produced were re-transformed into 5-alpha competent E.Coli (NEB) according to the 
following protocol adapted from NEB (C2987H/C2987I): 
* Perform steps 1-6 in the tube provided 
1. Thaw E.Coli (stored at -80°C) for 15 min on ice before adding 1μl of the 
antibody plasmid of interest 
a. Make a separate tube for each CMV antibody used in this study (Table 
1) 
2. Incubate cells on ice for 30 min 
3. Heat-shock the cells in a 42°C water bath for 30 seconds 
4. Add 1ml of stable outgrowth medium (NEB) to each tube 
5. Incubate tubes at 37°C for 1 hour in the rotation tray 
6. Use the bunsen burner flames to create a "sterile field": 
a. Plate 200μl of cells onto Luria broth (LB) agar plates with Ampicillin 
7. Leave plates to grow overnight at 37°C 
A single colony was picked and inoculated in 250mL of LB culture with 250μl 
of 1000x Ampicillin. The cells were allowed to grow overnight at 37°C on a shaking 
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platform. DNA was then harvested from the cells using PureYield Plasmid Maxiprep 
System (Promega, ref. A2393).  
To express the antibodies, Expi293F cells were grown to a density of 
10##%&&'/$) and transfected with expression plasmids following the Expi293F 
transfection protocol (Thermo Fisher Scientific) below: 
1. Day 0 
a. Add 7.5 × 107 cells to 25.5 mL of Expi293 Expression Medium in a 125-
mL flask. 
b. For each transfection, prepare the following: 
i. Dilute 30 μg of plasmid DNA in Opti-MEM Medium to a total 
volume of 1.5 mL. Mix gently. Filter the DNA. For this 
transfection 15 ug of light chain and 15ug of construct. 
ii. Dilute 81 μL of ExpiFectamine 293 Reagent in Opti-MEM 
medium to a total volume of 1.5 mL. Mix gently and incubate 
for 5 minutes at room temperature 
iii. After the 5-minute incubation, add the diluted DNA to the 
diluted ExpiFectamine 293 Reagent to obtain a total volume of 
3 mL. Mix gently. 
iv. Incubate the mixture for 20 minutes at room temperature to allow 
the DNA-ExpiFectamine 293 Reagent complexes to form. 
v. Add 3 mL of complex to each flask. Each flask should contain 
28.5 mL. 
2. Day 1 
a. After incubating cells for 20 hours, add 150 μL of Transfection Enhancer 
1 and 1.5 mL of Transfection Enhancer 2 to each flask. (Enhancers 1 
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and 2 can be combined prior to addition to the cell culture.) The final 
volume should be approximately 30 mL in each 125-mL flask. 
On Day 7 of the transfection, cells were harvested and spinned down. The 
supernatant was filtered and purified through gravity column purification. The protocol 
used is detailed below: 
1. Mix resin pro A or pro G  to resuspend 
2. Add 1-3mL into the column and let the fluid drip out. Add until the total volume 
of resin is 1-2mL (for 30 mL transfection) 
3. Flow 20% ethanol (25mL). Put fret about 1 cm above top of resin 
4. Flush with 25 mL 1X PBS, 0.1M NaOH, 1X PBS 
5. Flow supernatant through the column. Add 10mL 1X PBS. Collect all flow 
through in 50 mL conicals 
6. Swap out basin with 15 mL conical holder. Add 8-10 mL 100mM glycine (pH 
3) and collect 
7. In the 15 mL conical put 500 uL 1M Tris HCl pH 8. 
8. Add 2-4 mL 100mM glycine pH 2.7 and collect in the same 15mL conical tube. 
9. Buffer exchange 3X into 1X PBS in 30k MWCO column 
10. Reconstitute resin 
The transfection and purification procedures for the mAbs used in this study 
were performed by Andrew Hederman approximately 12 months prior to the start of 
this project and were kept at 4°C. 
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Cell culture and passaging 
Cell culture was carried out following previously described protocols (Bode et 
al., 2006). All the processes were carried out inside a class 2 biological safety hood 
(SterilGARDIII Advance, The Baker Company). The BeWo human choriocarcinoma 
cells used in this study originally came from ATCC, CCL-98. Cryopreserved cells at 
passage 7 were obtained from the -196℃ liquid nitrogen cell storage at the Thayer 
School of Engineering.  
Cells were cultured in DMEM-F12 + GlutaMAX (Gibco, ref 10565-018) 
containing 10% FBS (Biowest). To prepare the media, FBS stored at -20°C was thawed 
in a bead bath to 37°C and mixed with the DMEM-F12 + GlutaMAX medium; the 
solution was then vacuum filtered in a 0.2µm PES filter unit (VWR North American, 
cat 10040-436) and stored at 4°C up to use.  
Cell culture was carried out in polystyrene flasks T25 or T75 (CytoOne) with 
vented filter caps having a 0.2 µm hydrophobic membrane, and maintained at 37 °C, 
5% CO2, and 95% relative humidity inside an incubator (NAPCO Series 8000 WJ C02 
incubator, Thermo Scientific). 
First, the BeWo cell vial was thawed. Cells were slowly diluted in 20mL of pre-
warmed cell media, plated into a T75 cell culture flask, and let grow to confluency for 
5-6 days in the incubator. 
Cells were passaged when monolayer reached 80-90% confluency, which was 
monitored by visual inspection with light microscopy. Cell passaging followed these 
steps for a T75 cell culture flask:  
1. Warm up DMEM-F12 + 10%FBS media and 0.25% Trypsin (corning), both 
stored at 4°C, in a bead bath to 37°C  
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2. Remove current media from cell culture flask and wash monolayer with 5mL of 
new, warm media to remove dead cells; remove wash media from flask 
3. Add 1mL of Trypsin, close flask and incubate for 3-5min in the incubator 
4. Visualize cells under light microscope to confirm trypsinization of cells 
5. Hand-tap the sides of the flask until cells detach from the flask; check for cell 
suspension under the light microscope 
6. Add 5mL of media to the flask to bring the total volume to 6mL, washing the 
walls in order to maximize cell harvesting; vigorously pipet the solution 3 times 
in order to break down cell clumps 
7. Transfer the desired volume into a new cell culture vial based on the desired 
split; complement flask with cell media up to volument recommended by the 
vial manufacturer 
a. For a 1:2 split from a T75 flask to a T75 flask for example, add 3mL of 
cell solution into 17mL of cell media 
8. Store cell culture flask in the incubator 
 
In this project, cell passage numbers 7-17 were used in this study, following a 
1:2, 1:3, 1:4, or 1:6 volume split to accommodate the timeline of the experiments. For 
cell passaging between T25 (25#$") and T75 (75#$") flasks, the cell volume 
calculations accounted for a 1:3 area ratio of the vials . The total volume of cells + 
media in T75 cultures was 20mL and in the T25 was 7mL, based on recommendations 
from the manufacturer (CytoOne). 
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Collagen-coating of microporous membrane 
The protocol was scaled from a 12-well transwell format (Bode et al., 2006) to 
the 24-well transwell used throughout this project based on the area ratio of their 
membranes: 1.12 #$" and 0.33 #$", respectively (Corning). Each Transwell was 
coated with a mixture of  7µL of human placental collagen (2.5 mg/mL) and 21µL of 
70% Ethanol, on its microporous membrane. The collagen was obtained from Sigma 
Aldrich (C5533-5MG),  and stored at -20°C; thawing of the sample took place at room 
temperature. All the process was carried out inside a class 2 biological safety hood 
(SterilGARDIII Advance, The Baker Company).  
After initial coating, the Transwell plates were placed in the running hood with 
no lid for 2-3 hours until complete dryness. Next, the hood was closed and the plate 
was left with no lid under the UV light for 1 hour. Finally, the plates were closed, sealed 
with Parafilm M, wrapped in foil, and stored at 4°C up to use. Before use, the plates 
were left in the running hood at room temperature for 30min.  
 
Cell seeding on the Transwell membranes 
BeWo cells were seeded in the Transwell inserts, either on the collagen-coated 
matrix or directly over the microporous membrane, depending on the experiment and 
the conditions tested. For more details on the experimental design, read the following 
sessions.  
Once seeded on the Transwells, cells were cultured in DMEM-F12 with no 
phenol red (Gibco, ref 21041025) containing 10% FBS (Biowest). The presence of 
phenol red in the culture media would increase the background fluorescence of samples 
and interfere in fluorescent measurements. Thus, for the Transwell experiments, the 
22 
same cell media, but with no phenol red, was used to culture the cell monolayer. The 
media was prepared as previously described above.  
The cell seeding process followed steps 1-6 of “cell culture and passaging”, 
followed by the additional procedure:  
1. Transfer cell solution into a 15mL conical and aliquot 100µL for cell 
count 
a. Cell count:  
i. Mix 10µL of cell solution + 10µL of trypan blue 
(Corning, ref 25900CI) inside a well of a 96-well plate 
ii. Load 10µL into a chamber of a counting slide and insert 
the slide into the cell counter (TC20 Automated Cell 
Counter, BIO RAD) 
2. Calculate volume of cell solution needed to make 1mL of cell stock 
solution at 5,000,000 cells/mL: 
*+&	+-	#%&&	'+&./0+1	($)) 	= 	5	6	10# 	#%&&'$)	 	6	
1$)
#%&&	#+.1/	 
3. Aliquote the volume of cells calculated above into a vial and spin cells 
down at 300g for 10min 
a. In the meantime: warm up DMEM-F12 + 10%FBS no phenol 
red (clear media), stored at 4°C, in a bead bath to 37°C  
4. To prepare cell stock solution: remove supernatant (red media) and 
resuspend cells in 1mL of warm, clear cell media, mixing vigorously 
5. Add cell stock solution in the Tranwell based on the desired number of 
seeded cells and complement with clear media up to the desired volume 
a. Example: desired final volume of 100 uL 
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Table 2: Example of cell solution stock and media volumes to be added during cell seeding 
Desired number of seeded 
cells 
Volume of cell stock 
solution (uL) per well 
Volume of complementary 
media (uL) per well 
25,000 5 95 
50,000 10 90 
100,000 20 80 
200,000 40 60 
 
6. Add media to the bottom chamber 
7. Store Transwell plate in the incubator 
 
Optimization studies in the Transwell model 
This optimization experiment aimed at finding a balance between utilizing the 
least amount of seeding cells and incubating the cell layer for the least amount of time 
to minimize the amount of material used and expedite the process of preparing the 
Transwells for permeability studies.  
Three variable conditions were tested in an iterative fashion: collagen coat vs. 
no collagen coat on the Transwells; seeding cell density; incubation time. In previous 
projects at the Ackerman Lab, researchers reported coating 24-well Transwell inserts 
with human placental collagen and cell seeding of 20,000 cells (6 × 10$ cells/#$") and 
100,000 cells (3 × 10! cells/#$") with respective incubation times of 7 days and 24 
hours to reach monolayer confluency. This information, supported by methods reported 
in the literature described in the introduction of this report, guided the selection of 
reference values tested in the optimization experiments conducted for this project.  
During all experiments, three polyester inserts without the Transwells were used 
to track the cell growth using light microscopy for visual guidance about the monolayer 
formation status. The inserts were prepared following the procedure of the experiment 
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being conducted and quantities were scaled up based on the area ratio of the 
insert:Transwell area. 
Confluency of the Transwells was assessed through a permeability test using 
FITC-dextran (40kDa): 750µL of clear cell media was added to the lower chamber and 
100µL of 0.25mg/mL of FITC-dextran was added to the upper chamber. 40µL of 
sample from the lower chamber was collected over time to track FITC-dextran transport 
across the monolayer. Samples were stored at 4°C in a black 96-well plate with clear 
bottom (Corning) and had their fluorescences measured in the plate reader (SpectraMax 
Paradigm) using the Tune cartridge, fluorescent read mode, endpoint read type, and 
known wavelengths for read: one wavelength pair, 485 nm for excitation and 535 nm 
for emission. A half-dilution series of FITC-dextran at 2mg/mL was used as a standard 
curve of the experiment.  
 
1. Collagen vs. no-collagen coat 
Two sets of Transwells were prepared, one with the collagen coat, and another 
one without any coat, as depicted in Figure 8. For each set, four seeding cell numbers 
were used in each well: 25,000 (7.57 × 10$ cells/#$"); 50,000 (1.5 × 10! cells/#$"); 
100,000 (3 × 10! cells/#$"); 200,000 (6 × 10! cells/#$"). The cell collagen coating 
and seeding procedure were followed as described above. Confluency of the Transwells 
was compared through the 
FITC-dextran permeability 
test, in which samples were 
collected at times 0hr, 6hr, 
and 24hr. The experiment 
was conducted once, in 
Figure 8: Setup for testing collagen coating (a) vs. no coating (b) 
on the Transwells 
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duplicates, and there was no incubation time before the FITC-dextran was added to the 
Transwells. 
 
2. Cell seeding density 
This variable aimed at evaluating the impact of the cell seeding density on the 
rate at which the monolayer was formed, since the optimal set up would be to use the 
minimal number of cells possible to form a cell layer in the least amount of time. 
Based on the results of the coating experiment described above, the Transwells 
were coated with human placental collagen, and seeded with BeWo cells, following the 
protocols previously described. As depicted in Figure 9, four seeding cell numbers were 
used in each well: 25,000 (7.57 × 10$ cells/#$"); 50,000 (1.5 × 10! cells/#$"); 
100,000 (3 × 10! cells/#$"); 200,000 (6 × 10! cells/#$").  
The collagen coating experiment above revealed FITC-dextran passage through 
the monolayer after 24hrs of cell seeding. Thus, for this experiment, the Transwells 
were incubated for 24 hrs prior to a permeability test, at 37°C, 5% CO2, and 95% 
relative humidity. In the FITC-dextran permeability test, samples were collected at 0hr, 
30min, 16hr, and 24hr. The experiment was conducted once, in duplicates.  
 
 
Figure 9: Schematics representing the total number of cells added to each well: 25,000 (7.57 × 10! 
cells/#$"); 50,000 (1.5 × 10# cells/#$"); 100,000 (3 × 10# cells/#$"); 200,000 (6 × 10# cells/#$"). 
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3. Incubation time 
Lastly, this set of experiments aimed at finding the minimal number of days of 
incubation time to reach monolayer confluency after cell seeding. Based on the 
experiments designed for the other two variables described above, incubation time of  
72 hrs (3 days) and 196 hrs (7days) were tested, building up on the previously data 
collected for incubation times of 30min, 6hrs, 12 hrs, 24 hrs, 24hrs and 30min, 40hrs, 
and 48hrs, through the collagen-coat and the cell seeding density experiments. 
Transwells were coated with human placental collagen, and seeded with BeWo 
cells, following the protocols previously described. Cell seeding of 200,000 cells/well 
(6 × 10! cells/#$") was chosen based on the results of the “cell seeding density” 
experiment. After cell seeding, the Transwells were incubated for 72 hrs or 196hrs prior 
to a permeability test, at 37°C, 5% CO2, and 95% relative humidity. In the FITC-
dextran permeability test,  samples were collected at 0hr, 30min, 12hr, and 24hr. The 
experiment was conducted once, in duplicates. Transwells with collagen-coat but no 
seeded cells were used as a positive control and Transwells with collagen-coat and 
200,000 cells but no FITC-dextran were used as a negative control.  
 
IgG translocation studies  
The optimized Transwell model was used for IgG transport studies of the CMV 




Figure 10: Overview of the IgG translocation study conducted in this project 
 
First, the microporous membrane of the Transwell insert was coated with human 
placental collagen, as described above. Then, 200,000 cells were seeded onto the 
collagen coat and incubated for 72 hours in clear cell media, with an upper chamber 
volume of 150µL and a lower chamber volume of 700µL, kept at 37°C, 5% CO2, and 
95% relative humidity. At day 3, monolayer confluency was monitored by visual 
inspection with light microscopy and confirmed through a permeability test using 
FITC-dextran (40kDa): cell media was removed from the Transwells and replaced by 
new clear cell media; 750µL was added to the lower chamber and 100µL of 0.25mg/mL 
of FITC-dextran was added to the upper chamber. 40µL of sample from the lower 
chamber was collected over time (0hr, 30min, 6hr, 12hr, 24hr) to track FITC-dextran 
transport across the monolayer. At time 24hr, 40µL of the upper chamber was collected 
to compare with the initial amount of FITC-dextran added to the Transwell system. 
Transwells with collagen-coat but no seeded cells and FITC-dextran, and Transwells 
with collagen-coat and 200,000 seeded cells after 3 days of incubation but no FITC-
dextran, were used as controls. The permeability test was conducted in duplicates. 
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Samples were stored at 4°C in a black 96-well plate with clear bottom (Corning) and 
had their fluorescences measured in the plate reader (SpectraMax Paradigm) using the 
Tune cartridge, fluorescent read mode, endpoint read type, and known wavelengths for 
read: one wavelength pair, 485 nm for excitation and 535 nm for emission. A half-
dilution series of FITC-dextran at 2mg/mL was used as a standard curve of the 
experiment.  
Once the monolayer confluency was confirmed, the Transwells were used for 
translocation studies of the CMV antibodies of interest, at day 4 of cell seeding. The 
procedure followed similar steps of the permeability test described above: cell media 
was removed from the Transwells and replaced by new clear cell media; 750µL was 
added to the lower chamber and 150µL of 30µg/mL of each antibody was added to the 
upper chamber. 40µL of sample from the lower chamber was collected over time (0hr, 
30min, 6hr, 12hr, 24hr) to track the IgG transport across the monolayer. At time 24hr, 
40µL of the upper chamber was collected to compare with the initial amount of 
antibody added to the Transwell system. Samples were stored at 4°C until analysis.  
Transwells with IgM (0.1 mg/mL, Southern Biotech) were used as negative 
control of the experiment. This antibody translocation study was conducted in 
duplicates and each Transwell contained only one type of antibody. Each control had 
its own well and was not added to the wells containing the IgG antibodies, as the effect 
of their interaction is still unknown and not the focus of this study. A layout of the setup 









Figure 11: Setup of Transwell plates for the IgG translocation study. (a) Detailed diagram of plate setup. 
Each well contained only one antibody type, and the study was conducted in duplicates, using three 24-
well plates in total (b) Schematic of a Transwell with IgG antibody. (c) Schematic of a Transwell with 
IgM antibody (negative control).  
 
Luminex assay 
Detection and quantification of IgG in the samples collected during the antibody 
translocation studies took place through a Luminex immunoassay. First, magnetic 
beads were pre-coated with analyte-specific capture antibodies. Then, the samples were 
conjugated with the beads and PE-labeled detection antibodies and analyzed in the 
Luminex instrument (Bio-Plex 3D suspension Array System, BIO RAD). 
Four different beads were used in this assay, based on the specificity of the 
mAbs selected for this project and the experimental controls. Antigens used were gB 
(recombinant Human cytomegalovirus Glycoprotein B/gB Protein 1mg/mL, Sino 
Biological Inc), gH pentamer (cytomegalovirus gH pentamer complex 1mg/mL, Native 
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Antigen), anti IgG, and IgM. Beads for anti IgG and IgM were obtained from a 
colleague in the lab. For gB and pentamer antigens, 400µL of beads were conjugated 
for each, following these steps: 
1. Vortex beads (10-15 seconds) and transfer the appropriate amount into 
eppendorf tubes 
a. Write down the bead number on top of the tube 
2. Place the tube on the magnetic column until all beads stick to the magnet (30 
sec- 1 minute). Remove buffer. Resuspend in 100 µL dH2O. Vortex beads (10-
30 sec) and place back on the magnet 
3. Resuspend in 80 µL 100 mM NaPO4 pH 6.2 (activation buffer) 
4. Add 10 µL EDC and NHS at 50 mg/mL (for both 10 mg into 200 µL activation 
buffer) 
a. Note: EDC is stored at -20C and NHS is stored at 4C. Keep sealed 
(parafilmed and in the dessicator) when not in use. These reagents are 
not very water soluble so make right before use and throw out if it’s left 
out in solution for >30 min. 
5. Wrap in foil and mix end-over-end for 20 minutes in rotation tray at room 
temperature 
6. Place the tube on the magnetic column. Wash 3X with 50 mM MES pH 5 
(coupling buffer). (Wash by vortexing 30 seconds, put on magnetic column, 
aspirate buffer) 
7. Suspend in 100 µL coupling buffer 
8. Add 25 ug protein per 400 µL beads and bring up to 500 µL coupling buffer 
9. Wrap in foil and mix end over end for 2 hours in rotation tray at room 
temperature 
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10. Place on magnet, aspirate buffer. Wash 3X in PBS-TBN 
11.  Resuspend in 200 µL in PBS-TBN (PBS-TBN is purchased and stored at 4C), 
wrap in foil, block 30 minutes with end-over-end mix in rotation tray at room 
temperature 
12. Wash once in PBS-TBN and resuspend in starting volume 
 
Conjugated beads were stored at 4°C for two weeks up to use. Bead number 27 
was conjugated with gB; bead number 28 was conjugated with Pentamer; bead 21 was 
conjugated with anti IgG; bead number 44 was conjugated with IgM.  
Prior to analysis, samples collected were 
incubated with the conjugated beads and PE-
labeled secondary antibodies for detection to form 
a bead-analyte-antibody complex as depicted in 
Figure 12. Samples and standard curve samples for 
IgG used mouse anti-human IgG Fc-PE (Southern 
Biotech, cat 904009) as the secondary antibody. 
Samples of IgM and IgM standard samples used 
mouse anti-human IgM-PE (Southern Biotech, cat 
902099). 
Preparation of the sample and incubation with beads and secondary antibodies 
followed the procedure used in the Ackerman Lab and detailed below. Operation of the 
Luminex instrument was performed by Sweta Shrestha, a Ph.D candidate in the lab.  
1. Add 5 uL of each sample into a 384-well plate  
a. Only use clear bottom plates, magnet can’t pull down beads in white 
bottom plates 
Figure 12: Overview of the Luminex 
detection scheme. Figure adapted 
from Thermo Fisher (LuminexTM 
Bead-Based Immunoassays Drive 
Immunoassays towards Higher-
Content Biomarker Discovery, 2016). 
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2. Prep bead master mix in assay wash buffer: 
a. [# wells + 20] * # plates * 45 uL = uL assay buffer 
b. [#wells + 20] * # plates * 500 beads/well ÷ 10,000 beads/ uL = uL of 
each bead 
3. Vortex and sonicate 1X bead mix for 30 seconds each. Add 45 uL bead mix to 
each plate 
4. Sticker cover the plate, wrap plate in foil, and incubate on shaker at 1000 rpm 
for 2 hours 
5. Prepare secondary antibody 
a. Volume secondary: 
i. [#wells +15] * 40 uL/well = uL assay buffer 
ii. Note: antibodies should be used at 0.65 ug/mL. Only use PE 
conjugated antibodies. Dilute antibody in the assay wash buffer, 
cover with foil, and place in the fridge until being used 
6. Prime plate washer into assay wash buffer. Wash plate (6 washes, takes 8 
minutes) 
7. Add 40 uL of secondary antibody per well. Vortex 30 seconds, sonicate 30 
seconds. Repeat vortex/sonication 
8. Cover plate with sticker cover, wrap in foil. Incubate 1 hr on shaker 
9. Prime plate washer into sheath fluid and wash 
10. Use plate washer to add 40 or 50 uL (or add manually) 
a. If you added 40 uL sheath, pick up 35 uL. If you added 50 uL, pick up 
42 uL 
11. Bio-rad metal cover the plate and run on Luminex. No need to vortex or sonicate 
12. Follow instructions for cleaning the Luminex prior to use 
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Results 
Optimization studies in the Transwell model 
Determination of optimal parameters for creating a confluent cell layer in the 
Transwells were guided by the data collected in the FITC-dextran permeability studies. 
Fluorescence values were converted into estimated concentration (mg/mL) through 
linear regression of a FITC-dextran standard curve. Analysis of the data revealed that 
the final Transwell model must have a collagen coat, be seeded with 200,000cells/well 
for a 24-well plate (6 × 10! cells/#$"), and have an incubation of 3 days, at 37°C, 5% 
CO2, and 95% relative humidity for cell growth into a confluent layer.  
 
Collagen vs. no-collagen coat 
FITC-dextran permeability across the Transwells revealed a significant 
difference in the amount of analyte detected for collagen-coated inserts vs. inserts with 
no coat, as can be seen by comparison of graphs in Figure 13 (a) and (b). After 24hrs 
of cell seeding, for example, the Tranwells coated with 200,000 cells/well indicated a 
final FITC-dextran concentration of 0.15mg/mL for no-coat Transwells and 
0.027mg/mL for the collagen-coated Transwells. Therefore, the collagen-coated 
Transwells were able to retain more FITC-dextran than no-coat Transwells, indicating 
that a collagen matrix on the microporous membrane facilitates and/or expedites the 
formation of a cell layer, and should be added to the steps of Tranwell preparation in 
translocation studies. Raw data of this experiment in fluorescence units and a table with 












Figure 13: Graphs of FITC-dextran permeability across the Transwells, assessed by concentration 
plotted over time. This permeability test was performed right after cell seeding. (a) Graph of collagen 
coated Transwells; (b) Graph of Transwelss with no coat; (c) Standard curve used to obtain values 
plotted in graph (a); (d) Standard curve used to obtain values plotted in graph (b); 
 
Cell seeding density 
Comparison of FITC-dextran detection across Transwells seeded with different 
cell densities revealed a huge gap in the permeability of the membranes. As can be seen 
in graphs in Figure 14 (a) and (b), Transwells with less seeded cells allowed the passage 
of more FITC-dextran across the monolayer, suggesting that FITC-dextran 
permeability is inversely proportional to the number of seeded cells. For example, for 
Tranwells seeded with 25,000 cells/well (7.57 × 10$ cells/#$"), 0.099 mg/mL of FITC-
dextran was detected at 24hrs, while only 0.034 mg/mL of FITC-dextran was detected 
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in the Transwells coated with 200,000 cells/well (6 × 10! cells/#$"). As expected, this 
data suggests that the more cells are added to the initial seeding of the Transwell 
membranes, the faster the monolayer will reach confluency. Thus, seeding cell density 
of 200,000 cells/well (6 × 10! cells/#$") was selected to expedite the monolayer 
formation in the inserts. Raw data of this experiment in fluorescence units and a table 






Figure 14: Graph of FITC-dextran permeability across Transwells with different seeding densities over 
time. Transwells were incubated for 24hrs after cell seeding and prior to this permeability experimente.  





Analysis of the data collected in the collagen-coat (Figure 13 (a)) and seeding 
cell density (Figure 14 (a)) experiments revealed that monolayer confluency was not 
obtained immediately after cell seeding or after a 24hrs incubation for any of the cell 
seeding densities tested, since a significant amount of FITC-dextran was still being 
detected in the samples collected. This indicated the need for more incubation time prior 
to the permeability tests to allow for cell growth.  
However, permeability data collected after 3 days of incubation (Figure 15 (a)) 
and after 7 days of incubation (Figure 15 (b)) for 200,000 cells/well revealed that 
monolayer formation is reached after 3 days of cell seeding, since only 0.018 mg/mL 
of FITC-dextran was detected in the samples. This was further confirmed by the data 
collected in the IgG translocation studies, reported in the next section. Similar results 
were obtained for the monolayers incubated for 7 days, with detection of 0.16mg/mL 
of FITC-dextran, suggesting that even after 7 days of incubation, the monolayer is still 
viable to be used in permeability studies.  
Monolayer confluency should have indicated no FITC-dextran permeability. 
However, the FITC-dextran molecule used was 40kDa, which is approximately three 
times smaller than an IgG molecule (150kDa). The small size of the FITC-dextran used 
in this experiment justifies some small, natural, permeability across the cell layer. Also, 
since the Transwell plates were stored in the lab incubator, it might be possible that 
other researchers disturbed the system by rearranging the plates inside the incubator. 
Nevertheless, analysis of the raw fluorescence data (Appendix III) reveals that  around 
90% of the FITC-dextran originally added was being retained by the cell layer. 
Therefore, small concentrations of FITC-dextran in the samples collected did not 
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necessarily indicate the need of more incubation time to reach confluency. The 
similarity in FITC-dextran concentration obtained for incubations of 3 days and 7 days 
might suggest that the system possibly reached a plato of FITC-dextran permeability 
across the cell layers, regardless of more incubation time. Raw data of this experiment 
in fluorescence units and a table with the estimated concentrations plotted in Figure 15 










Figure 15: Graphs of FITC-dextran permeability across the Transwells, assessed by concentration 
plotted over time.  (a) Graph of Transwells after 3-day incubation; (b) Graph of Transwelss after 7-day 
incubation; (c)  Standard curve used to obtain values plotted in graph (a);  (d) Standard curve used to 
obtain values plotted in graph (b). 
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Preferential IgG transferring in the BeWo Transwell model 
Data of the FITC-dextran permeability test after 3 days of Transwell incubation 
confirmed the confluency of the BeWo cell layer. As can be seen in Figure 16 (a), the 
concentration of FITC-dextran detected in the samples replicate the concentrations 
obtained in the prior permeability test after a 3-day incubation (Figure 15 (a)). Raw data 
of this experiment in fluorescence units and a table with the estimated concentrations 






Figure 16: Graph of FITC-dextran permeability across the Transwells after a 3-day incubation, assessed 
by concentration plotted over time. (b) Standard curve used to obtain values plotted in graph (a). 
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As can be seen in Figure 17, monolayer confluency of the Transwells after a 3-
say incubation was further confirmed by the absence of IgM antibodies detected in the 
samples during the IgG translocation study, since the IgM control signal is aligned with 
the IgM background signal. At the 24-hours point, average MFI of the two samples 
collected indicated higher signal than the IgM background point, however, the standard 
error bars at that point account for possible mistakes in sample manipulation or 
collection, disturbance of the monolayer from previous sample collections, or 
disturbance of the system by fellow researchers in the lab while in the incubator. Figure 
17 further depicts the relative translocation efficiencies between the different IgG 
antibodies studied, with IgG4 1G2 having the best transferring performance.  
 
 
Figure 17: Antibody translocation across the BeWo Transwell layer. Mean fluorescence intensity (MFI) 
plotted over time (0hrs, 30min, 6hrs, 12 hrs, 24hrs) is proportional to the amount of antibody detected 
in each sample. Anti-human IgG Fc-PE was used for the detection of IgG and anti-human IgM-PE was 
used for the detection of IgM. The IgM control curve is plotted with its standard error bars. 
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Further analysis of the data in Figure 17 by IgG subclasses (Figure 18) reveals 
that IgG3 has the worst relative transferring, regardless of its specificity. On the other 
hand, IgG4 and IgG2 showed the best relative transferring performance overall. For the 
specificities 1G2 and 8I21, IgG4 indicated the highest preferential transferring. For 
specificities ITC33 and 916, IgG2 transferring surpassed that of the other mAbs. Across 











Figure 18: Antibody translocation across the BeWo Transwell layer by IgG subclass. Mean fluorescence 
intensity (MFI) plotted over time (0hrs, 30min, 6hrs, 12 hrs, 24hrs) is proportional to the amount of 
antibody detected in each sample. (a) Plot of IgG1 mAbs. (b) Plot of Ig21 mAbs. (c) Plot of IgG3 mAbs. 
(d) Plot of IgG4 mAbs. 
 
Analysis of the data in Graph 5 by mAb specificities (Figure 19) reveals that 
IgG 1G2 has the best transferring performance across the cell layer, regardless of its 
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subclass. For the other specificities, no translocation pattern linking mAb specificity 
and subclass was observed.  
However, comparison of relative MFI values of each mAb specificity within the 
same IgG subclass suggests preferential transferring of certain specificities depending 
on the subclass analyzed. For IgG1, 8121 and 916 mAbs had the worst transferring 
performance. For IgG2, 8I21 and ITC33 had the worst transferring performance. For 
IgG3, 8I21 and 916 and had the worst performance. Finally, for IgG4, ITC33 and 916 
had the worst translocation performance. Here, it is important to highlight that such 
observations can be used as a guidance for future researchers but still require more data 
to get quantified and statistically compared, since the experiment was run only once, 










Figure 19: Antibody translocation across the BeWo Transwell layer by mAb specificity. Mean 
fluorescence intensity (MFI) plotted over time (0hrs, 30min, 6hrs, 12 hrs, 24hrs) is proportional to the 
amount of antibody detected in each sample. (a) Plot of 1G2 mAbs. (b) Plot of 8I21 mAbs. (c) Plot of 




Studies about vertical immunization rely heavily on in-vitro models to 
extrapolate physiological conditions of the human placenta for antibody translocation 
studies. The BeWo Transwell model (Bode et al., 2006) presents itself as a reliable 
model to represent perfusion preferences of substances that agree with other complex 
ex-vivo models and to mimic the transplacental transport mechanism. However, despite 
being a consolidated method, the BeWo Transwell preparation has a wide variation of 
parameters. In this project, I optimized the BeWo Transwell model towards a more 
time-efficient preparation to reach monolayer confluency by investigating three 
variables: membrane coating, cell seeding density, and incubation time. The final ideal 
parameters for the Transwell setup based on the variables studied are collagen-coat over 
the microporous membrane, seeding cell density of 6 × 10! cells/#$" (200,000 
cells/well for the 24-well plate), and incubation time of 72 hrs (3 days). Such results 
agree with previous methods used by other researchers.  
As previously investigated by Bill Law in the Ackerman lab and published by 
Bode et al., adding collagen-coat to the Transwells is a necessary step towards preparing 
the setup for confluency, which is expected from a biological standpoint since the 
collagen works as a scaffold for the cells to grow.  
The need of a higher cell seeding density to expedite the confluency of the 
monolayer confirms our initial hypothesis that Transwells seeded with higher cell 
densities will require less incubation time to reach monolayer confluency. The cell 
seeding density value proposed, 6 × 10! cells/#$" (200,000 cells/well for the 24-well 
plate), falls within previously reported cell seeding densities ranges discussed in the 
introduction of this report (1.0× 10! cells/#$" to 1.0 × 10# cells/#$"), which gives us 
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confidence that such value will not underflow or overflow the surface area of the 
Transwell and potentially affect the growth of a viable, healthy monolayer.  
Finally, the incubation time proposed of 72 hrs (3 days) is in agreement with the 
incubation time used by Aengenheister et al., which further supports our findings. This 
incubation time is smaller than the 5-7 day incubation period that most research groups 
previously reported (Bode et al., 2006; Cartwright et al., 2012; Huang et al., 2016; 
Rytting et al., 2012), and meets our goal of optimizing the Transwell model in order to 
achieve a confluent monolayer in the most time-efficient manner and expedite the 
research process in biotech laboratories. Compatible FITC-dextran permeability results 
from the 3-day incubation and the 7-day incubation suggests that even after 7 days of 
incubation, the monolayer is still viable to be used in permeability studies. This means 
that researchers can prepare their Transwells, incubate them for 3 days, run experiments 
in a confluent cell layer, and, if needed, repeat experiments using the same cell layer up 
to 7 days of cell seeding, which can further save up lab-work time.  
IgG translocation studies using the BeWo Transwell model revealed that IgG3 
had the worst relative transferring, regardless of its specificity, and that IgG4 and IgG2 
demonstrate the best relative transferring performance overall. This contradicts our 
initial hypothesis that IgG preferential transferring in the Transwell model would follow 
the preferential transfer in-vivo: IgG1 > IgG4 > IgG3 > IgG2 (Bt et al., 1996; Malek et 
al., 1994, 1996). One possible cause of such discrepancy might be a limitation in the 
BeWo Transwell model in mimicking the IgG preferential transfer in-vivo. However, 
given the physiological similarities of the cell line cultured on the Transwell inserts to 
the placental tissue, it is likely that such results are being influenced by the IgG 
specificity of the mAbs studied.  
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In the past, studies about IgG-FcRn binding reported that the Fab domain does 
not interfere with FcRn binding (Neuber et al., 2014). However, recent studies 
characterizing the binding of 50 IgG molecules showed the opposite (Piche-Nicholas et 
al., 2018). In 2018, Piche-Nicholas, Avery, King et al. demonstrated that domains distal 
from the Fc can influence IgG binding to the FcRn domain and affect pharmacokinetics. 
The researchers found out that the mutated IgG molecules in their variable domains had 
their binding affinity to the FcRn altered in-vitro. Extending such findings into our 
study, it can be hypothesized that IgG preferential transfering of the CMV mAbs 
studied did not correlate with previously reported preferential transferring in-vivo due 
to differences in antibody specificity. Up to this date, there is no study that attempted 
to evaluate IgG preferential transferring in the context of CMV, limiting our ability to 
compare our results with other published data within the same field of study. 
However, the variable domain influence of IgG-FcRn binding is supported by 
the data collected in this experiment, as each mAb specificity demonstrated a distinct 
preferential translocation across the cell layer. The IgG 1G2, for example, had the best 
transferring performance regardless of its subclass. It would be valuable to investigate 
in the future how the combination of subclass and specificity affect the IgG-FcRn 
binding, so we can leverage IgG translocation by designing mAbs with such 
characteristics.  
 
Recommendations for Future Work 
Co-culture model in the Transwell inserts 
Although the BeWo monolayer Transwell model is a consolidated method for 
translocation studies in-vitro, it is not without its downsides. The single cell layer does 
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not fully resemble the physiological structure of the placental barrier, which might limit 
the ability of the model to offer predictions to in-vivo situations about larger and more 
complex molecules such as antibodies. Co-culture models using different cell lines and 
simulating the in-vivo dynamic environment have recently been developed to improve 
the in-vivo resemblance of the Transwell model and have proven to be reliable systems 
in translocation studies (Aengenheister et al., 2018; Huang et al., 2016; Levkovitz et 
al., 2013). The model developed by  et al., for example, uses a co-culture of BeWo cells 
and microvascular human placental venous endothelial cell line (HPEC-A2) and allows 
the translocation of a large variety of low to high molecular weight compounds and 
nanoparticles (Aengenheister et al., 2018). In future studies, such a model should be 
explored as a means of minimizing the physiological limitations of the single-layer 
BeWo Transwell model used in this project. Other studies could potentially investigate 
optimization parameters for the preparation of this co-culture model, following the 
experimental approach used in this project and using the parameters of the single-cell 
layer model as a starting reference, in order to assess the trade off between setting up a 
more complex model with the cell seeding density needed and the Transwell incubation 
time. 
 
Preferential transferring of IgG across the Transwell monolayer 
 Despite observing relative differences in the transport of the antibodies studied, 
further investigation must be conducted to quantify their permeability rates and 
statistically assess whether such rates are significantly different.  
 While a different IgG subclass preferential transfering was observed in the 
BeWo Transwell model than the one reported from in-vivo studies, with the current 
data it is not possible to know whether such differences are a limitation of the BeWo 
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Transwell model or a reflection of how the CMV-specific mAbs produced would 
behave in-vivo. Thus, future studies should investigate how the IgG transferring in the 
BeWo Transwell model compares to the IgG transferring in-vivo for the same antibody 
subclasses and specificities. Since in-vivo studies of IgG transferring require complex 
organization, one could select a previously published IgG transferring in-vivo and 
replicate the transport study of the same antibody types in the Transwell model to 
compare the resulting preferential transfering to those obtained in the published study.  
 Additionally, up to this date, transport studies using the BeWo Transwell model 
reported mainly the investigation of nanoparticles and small molecules, and no study 
was found comparing IgG transferring in the context of subclasses. Thus, further 
investigation is required in order to assess whether the IgG preferential transfering 
results obtained in this project would be replicated when studying the transport of mAbs 
subclasses with other specificities.  
 
CMV-specific studies 
Over the last two years, there have been research efforts in the Ackerman Lab 
in conjunction with collaborators around the world to study the 16 CMV mAbs 
developed in-house and used in this project. There is still much work to further 
characterize these antibodies and their immune response in the context of vertical 
immunization. However, based on the results from the IgG translocation studies in this 
project, future studies can focus on the further investigation of IgG2 and IgG4 with the 
1G2 specificity, since these subclasses and specificity demonstrated preferential 
transferring across the BeWo cell layer.  
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In our study, it was not possible to establish a translocation pattern linking mAb 
specificity and subclass. This might be because these two variables affect each other 
during FcRn binding, resulting in a unique mAb specificity-subclass preferential 
transferring for each of the antibodies studied. Given the differences in preferential 
transferring observed, future studies could focus on investigating means of mutating 
the complementarity-determining regions (CDRs) of the variable domains of the CMV 
mAbs, just as the mutations reported by Piche-Nicholas, Avery, King et al. Altering 
these IgG molecules can be used to leverage IgG-FcRn binding and subsequent 





















Appendix I: Fluorescence data of collagen-coat vs. no coat experiment 
 
 
Table 3:  Raw fluorescence data of FITC-dextran permeability across the monolayer for the collagen-
coated transwells 


















0 2684362 2570768 2568483 2587135 2405238 2465883 2239656 2288823 
6 2739840 2776988 2717706 2622114 2625878 2618534 2552624 2798200 
24 2965496 2822920 2798498 2769424 2839154 2855156 2502318 2464379 
24 (upper 






































Table 5: Estimated concentration values plotted on Figure 13 (a) 
Time 
(hours) 25k cells 50k cells 100k cells 200k cells 
0 0.03134925 0.03005469 0.02635364 0.0254794 
6 0.0347537 0.03245099 0.03120982 0.02689414 







Table 6: Raw fluorescence data of FITC-dextran permeability across the monolayer for no-coat 
Transwells 


















0 2079660 2948110 3979249 3068706 233119 1978277 3762978 2874603 
6 2852607 1073101 1938649 3247669 4913056 3361404 3846659 3972372 
24 4241756 4263357 5908416 5235502 9146745 6197890 6365292 8938859 
24 (upper 

































Table 8: Estimated concentration values plotted on Figure 13 (b) 
Time 
(hours) 25k cells 50k cells 100k cells 200k cells 
0 0.08846851 0.05530423 0.09154334 0.07640661 
6 0.09732082 0.10073324 0.07759457 0.06814913 












Appendix II: Fluorescence data of cell seeding density experiment 
 
Table 9: Raw fluorescence data of FITC-dextran permeability across the monolayer in the cell seeding 
density experiment 


















0 136890 136000 132627 137189 137484 135979 134724 137733 
0.5 166672 185497 196184 156327 186503 158093 175909 147022 
6 556107 478493 545173 435046 410232 415413 449067 453542 
16.5 696222 1294012 817441 682718 611175 657486 612103 606750 
24 970639 2294710 878263 1394416 854021 1225160 836376 683498 
24 (upper 




































Table 11: Estimated concentration values plotted on Figure 14(a) 
Time 
(hours) 25k cells 50k cells 100k cells 200k cells 
Cell Media 
Background 
0 -0.003786195 -0.003892694 -0.003766343 -0.003801196 -0.001577364 
0.5 -0.001039569 -0.00102772 -0.000317669 -0.002052521 -0.001577364 
6 0.022603298 0.020719265 0.015364038 0.018030461 -0.001577364 
16.5 0.055711301 0.03873262 0.030712357 0.028986755 -0.001577364 




























Appendix III: Fluorescence data of incubation time experiment 
 
Table 12: Raw fluorescence data of FITC-dextran permeability across the monolayer for 3-day 
incubation 










200k cells no 
FITC (sample 1) 
200k cells no FITC 
(sample 2) 
0 146605 144798 143940 148099 146009 149782 
0.5 180103 183185 154120 154843 146857 144531 
6 548582 512235 240005 256386 160157 155630 
12 727686 809442 380127 3893786 183837 155617 
24 972128 1089004 584235 513602 216982 163768 
24 (upper 
























Table 14: Estimated concentration values plotted on Figure 15(a) 
Time 
(hours) No cells 200k cells 
200k cells (no 
FITC) 
0 -0.0068487 -0.0068288 -0.0067112 
0.5 -0.0045959 -0.0062984 -0.0068492 
6 0.01726333 -0.0004247 -0.0060845 
12 0.03219003 0.00813408 -0.0053429 








Table 15: Raw fluorescence data of FITC-dextran permeability across the monolayer for 7-day 
incubation 










200k cells no 
FITC (sample 1) 
200k cells no FITC 
(sample 2) 
0 132391 136400 134598 128115 138311 130421 
0.5 178217 156328 145693 138310 131798 143953 
6 373258 361768 181631 249714 135899 137067 
12 550758 602925 248515 433816 132620 126710 
24 883425 960068 341888 675139 184398 139677 
24 (upper 






























Table 17: Estimated concentration values plotted on Figure 15(b) 
Time 
(hours) No cells 200k cells 
200k cells (no 
FITC) 
0 -0.0025943 -0.002655 -0.002596 
0.5 -0.0006206 -0.0021917 -0.0023853 
6 0.01140007 0.00218145 -0.0024689 
12 0.02396631 0.0077557 -0.0028782 








Appendix IV: Fluorescence data of FITC-dextran permeability prior to IgG 
translocation investigations 
 
Table 18: Raw fluorescence data of FITC-dextran permeability across the monolayer for the 3-day 
incubation prior to IgG translocation studies 










200k cells no 
FITC (sample 1) 
200k cells no FITC 
(sample 2) 
0 119694 136220 130039 131120 130674 132551 
0.5 170328 187951 147501 146919 132019 147934 
6 382816 437423 229592 260557 141857 142808 
12 606506 540086 308448 379165 136834 139658 
24 715954 858162 367687 587868 133408 136581 
24 (upper 
























Table 20: Estimated concentration values plotted on Figure 16 
Time 
(hours) No cells 200k cells 
200k cells (no 
FITC) 
0 -0.0042499 -0.0040746 -0.0040056 
0.5 -0.0008283 0.0015 -0.0034464 
6 0.01461305 0.00357954 -0.0032889 
12 0.02552165 0.01017992 -0.0035621 
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